CRI Discovery Logo

Exploring our immune system to find new answers to cancer.

See CRI Discovery programs

The Path Forward to a Cure

Scientific discovery is the only path forward to finding cancer cures. The Cancer Research Institute is dedicated to unraveling the complex biology of cancer and the immune system to produce new insights that lead to better treatment options for cancer patients.

Image looking upward at a scientist using a dropper

“The goal of our research is to develop and apply genome-scale technologies to study fundamental properties of the immune system in cancer immunity and immunotherapy.”

CRI Lloyd J. Old STAR
Stanford University

Fueling Scientific and Medical Innovation

By spurring fundamental learning about the basic cellular and molecular mechanisms involved in anti-cancer immune response and pushing that learning forward into preclinical and clinical research, CRI is fueling scientific and medical innovation that saves lives.

CRI’s basic and translational research funding programs include:

Scientist with gloves on stands and works at a lab

CRI Irvington Postdoctoral Fellowship Program

The CRI Irvington Postdoctoral Fellowship Program provides support to fund, mentor, and train young immunologists and cancer immunologists at top universities and research centers around the world. Fellowships are offered under three tracks: Postdoctoral Fellowships, Postdoctoral Fellowships to Promote Racial Diversity, and our NEW Postdoctoral Fellowships in Immuno-Informatics coming in 2023.

One hand holds a dropper, the other a vial

Clinic and Laboratory Integration Program (CLIP)

The CRI Clinic and Laboratory Integration Program (CLIP) supports pre-clinical and translational research that can be directly applied to optimizing cancer immunotherapy in the clinic. CLIP grants are awarded to qualified scientists exploring clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies.

A scientist with safety goggles works in a lab

Lloyd J. Old STARs (Scientists TAking Risks)

The CRI Lloyd J. Old STAR Program—Scientists TAking Risks—provides long-term funding to mid-career scientists, giving them the freedom to pursue high-risk, high-reward research at the forefront of discovery and innovation in cancer immunotherapy. The Lloyd J. Old STAR program provides up to $1.25 million over a five-year period to tenure-track assistant professors (minimum 3 years) and associate professors (maximum 3 years).

Technology Impact Award

Technology Impact Awards

The Cancer Research Institute Technology Impact Award provides seed funding of up to $200,000 to be used over 12-24 months to address the gap between technology development and clinical application of cancer immunotherapies. These grants aim to encourage collaboration between technology developers and clinical cancer immunologists

CRI Clinical Innovators

Clinical Innovators

Innovative immunotherapy clinical trials proposed by academic researchers are vitally important to improving patient outcomes. The Clinical Innovator will support novel clinical studies that address areas of high unmet need in cancer and seek mechanistic insights into clinical response with a goal of predictive biomarker discovery. CRI will advise on selected studies in a coordinated effort to optimize clinical trial design and translational studies.

This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.